PZM21 Opioid Modulator Biased Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid therapies, such as morphine, are limited by their potential for respiratory depression and constipation, and there is a need for agonists that specifically target the Gi-protein pathway of μ opioid receptors to reduce these side effects while maintaining analgesic efficacy.
Innovation Solution
Development of a compound, PZM21, with a unique scaffold that selectively activates μ opioid receptors with minimal β-arrestin2 recruitment, reducing the affective component of pain without altering reflexive behaviors and minimizing respiratory depression, and is designed to modulate opioid receptor activity to reduce addiction liability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional opioids such as morphine are used for pain treatment, then analgesic efficacy is improved, but respiratory depression and constipation occur as harmful side effects
Solution Approach 1:
The patent applies local quality by designing a compound (PZM21) with specific structural features (formula I) that create selective signaling properties at the μ-opioid receptor. The molecular structure enables preferential activation of the Gi-protein pathway while minimizing β-arrestin2 recruitment, thereby producing localized therapeutic effects (analgesia) without triggering harmful downstream pathways (respiratory depression, constipation).
Solution Approach 2:
The invention changes the signaling parameter profile of μ-opioid receptor activation. By modifying the ligand structure to achieve biased agonism, the patent alters the relative activation levels of different signaling pathways (Gi-protein vs. β-arrestin2), maintaining beneficial effects while reducing harmful ones. This is achieved through specific molecular modifications in compounds of formula (I) that tune receptor conformation and signaling bias.
2Reliability
If traditional opioids are used for pain treatment, then analgesic efficacy is improved, but constipation occurs as a harmful side effect
Solution Approach 1:
The compound PZM21 exhibits local quality in its signaling profile by selectively activating Gi-protein coupled pathways while sparing β-arrestin2 mediated pathways. This selective activation pattern produces analgesic effects through Gi-protein signaling in the CNS without triggering β-arrestin2 dependent gastrointestinal motility changes, thereby eliminating constipation as a side effect while maintaining pain relief.
Solution Approach 2:
The patent converts the harmful β-arrestin2 signaling pathway into a beneficial selectivity feature. By designing a ligand that actively avoids β-arrestin2 recruitment, the invention transforms what would normally be a source of side effects (β-arrestin2 activation leading to constipation) into a defining characteristic of a safer opioid analogue, where the absence of this pathway activation becomes the therapeutic advantage.
3Adaptability or versatility
If opioids activate dopaminergic reward circuits, then euphoric effects are produced, but addiction liability increases
Solution Approach 1:
The patent extracts the harmful dopaminergic reward circuit activation from the overall opioid effect profile. By designing PZM21 to selectively engage Gi-protein pathways and avoid β-arrestin2 recruitment, the compound selectively removes the euphoric/adictive dopaminergic component while preserving the analgesic Gi-protein mediated effects. This separation allows pain relief without the reinforcing euphoric effects that drive addiction.
Solution Approach 2:
The invention segments the opioid signaling into distinct functional components by achieving pathway-selective activation. The compound divides the traditional monolithic opioid effect into separate Gi-protein mediated analgesia and β-arrestin2 mediated side effects, selectively activating only the beneficial segment (Gi-protein) while leaving the harmful segment (β-arrestin2, which links to dopaminergic reward and addiction) inactive.
Data Source
AI summary
Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.